H.R. 5364 – Medical Cannabis Research Act

Most people would be surprised to hear that Israel is the global leader in medical cannabis research. Not a surprise here considering that Israel is already known as an agricultural heavyweight and first allowed patients with qualifying conditions to use cannabis in the early 1990’s. Additionally, Israel does not have the federal law prohibition we have to endure. Israel’s embrace to allow for medical cannabis and medical cannabis research has opened the doors to allow scientists to conduct research without the fear of interruption by the government. The Israelis have been so successful in developing high quality cannabis strains that you cannot get anywhere else that they are posed to export this crop which some analysts believe could bring in as much as $4 billion in yearly revenue and improve the quality of ongoing medical research involving cannabis.

The Anti-Federal U.S. Climate

The Federal Controlled Substances Act (“CSA”) 21 U.S.C. § 812 classifies marijuana as a Schedule 1 substance with a high potential for abuse, no currently accepted medical use in treatment, and lack of accepted safety for use under medical supervision. Although you can still face federal criminal charges for using, growing, or selling weed in a manner that is completely lawful under California law, the federal authorities in the past have pulled back from targeting individuals and businesses engaged in medical marijuana activities. This pull back came from Department of Justice (“DOJ”) Safe Harbor Guidelines issued in 2013 under what is known as the “Cole Memo”.

The Cole Memo included eight factors for prosecutors to look at in deciding whether to charge a medical marijuana business with violating the Federal law:

Does the business allow minors to gain access to marijuana?

Is revenue from the business funding criminal activities or gangs?

Is the marijuana being diverted to other states?

Is the legitimate medical marijuana business being used as a cover or pretext for the traffic of other drugs or other criminal enterprises?

Are violence or firearms being used in the cultivation and distribution of marijuana?

Does the business contribute to drugged driving or other adverse public health issues?

Is marijuana being grown on public lands or in a way that jeopardizes the environment or public safety?

Is marijuana being used on federal property?

Since 2013, these guidelines provided a level of certainty to the marijuana industry as to what point could you be crossing the line with the Federal government. But on January 4, 2018, Attorney General Jeff Sessions revoked the Cole Memo. Now U.S. Attorneys in the local offices throughout the country retain broad prosecutorial discretion as to whether to prosecute cannabis businesses under federal law even though the state that these businesses operate in have legalized some form of marijuana.

Rohrabacher-Blumenauer Amendment (f/k/a Rohrabacher-Farr Amendment)

Medical marijuana is now legal in 29 states plus the District Of Columbia and recreational marijuana is legal in 8 states plus the District Of Columbia. Building on the DOJ’s issuance of the Cole Memo, in 2014 the House passed an amendment to the yearly federal appropriations bill that effectively shields medical marijuana businesses from federal prosecution. Proposed by Representatives Rohrabacher and Blumenauer, the amendment forbids federal agencies to spend money on investigating and prosecuting medical marijuana-related activities in states where such activities are legal.

The amendment states that:

None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.

This action by the House is not impacted by Sessions’ recent change of position with the DOJ. However, unless this amendment gets included in each succeeding federal appropriations bill, the protection from Federal prosecution of medical marijuana businesses will no longer be in place.

Fortunately for medical marijuana businesses in the last budget extension approved by Congress, this amendment was included so these protections continue to September 30, 2018. This means that the DOJ is precluded from spending funds to circumvent any of the foregoing states from implementing their medical cannabis laws.

Clearly, to avail yourself of the protections of the amendment, you must be on the medical cannabis side and you must be in complete compliance with your State’s medical cannabis laws and regulations. You may not be covered under the amendment if you are involved in the recreational cannabis side even if legal in the State you are operating.

Supply Of U.S. Cannabis Source For Medical Research Is Severely Limited And Inferior

Foreign pharmaceutical companies are getting FDA approval for cannabis-based drugs. Just recently the successful clinical trials of GW Pharma (United Kingdom) and the subsequent approval of Epidiolex highlight the opportunity to use science to justify making medical cannabis an option to patients and setting the U.S. back further from developing this science.

Unfortunately, the one U.S. source for medical cannabis research (that is the University Of Mississippi) cannot provide the quality and strains needed for research that foreign countries (most notably Israel) can produce.

H.R. 5364 – Medical Cannabis Research Act

This week, the House Judiciary Committee met to discuss the Medical Cannabis Research Act (H.R. 5634), sponsored by Matt Gaetz (R-FL) with 23 Democrats and 19 Republicans cosponsoring it. The legislation would compel the DEA to end the monopoly held by the University of Mississippi on the production of medical cannabis for research with the addition of at least two other manufacturers. While the Bill will advance to the floor of the House, which in and of itself is truly historic, the lack of Congress to support any progressive legislation on cannabis may see this bill like others reach a dead-end.

What Should You Do?

Unlike the citizens of Israel, given the illegal status of cannabis under Federal law you need to protect yourself and your marijuana business from all challenges created by the U.S. government. Although cannabis is legal in California, that is not enough to protect you. Be proactive and engage an experienced attorney-CPA in your area. Let the tax attorneys of the Law Offices Of Jeffrey B. Kahn, P.C. located in Orange County, Inland Empire (Ontario and Palm Springs) and other California locations protect you and maximize your net profits.